Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBeing on Wegovy means taking a once-weekly semaglutide injection that gradually reduces appetite — most people notice they feel full sooner, think about food less, and find portion sizes naturally shrink over the first few weeks. It is a prescription-only medicine requiring clinical assessment before a prescriber can decide whether it is right for you. The experience varies from person to person, shaped by dose, lifestyle, and individual tolerance, but there are consistent patterns that anyone considering treatment tends to find useful to understand before they start.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: it is the morning after your first injection, and you are half-expecting to feel transformed. For most people, nothing dramatic happens immediately. The starting dose is low by design, its job is to let your body adjust, not to produce rapid weight loss from day one. You might notice mild nausea later that day, or a slightly earlier sense of fullness at dinner. That is broadly the pattern the semaglutide pathway tends to follow in the opening weeks.
Over those first four weeks, many people begin noticing they leave food on their plate without trying to. The background noise about snacking quietens. One thing our prescribers hear most weeks is patients saying they did not expect the change to feel this unremarkable at first, and then suddenly realise they have eaten half their usual lunch and genuinely do not want the rest.
The Wegovy dose escalates roughly every four weeks, moving from 0.25 mg through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg as the standard maintenance dose (a 7.2 mg option is now also approved, subject to a prescriber's clinical assessment). Each step up can bring a brief return of nausea or digestive unsettlement. Staying hydrated and eating smaller, lower-fat meals around injection day helps considerably, as NHS guidance on semaglutide notes.
Gastrointestinal symptoms are the headline, but the lived experience is more textured than a printed list suggests. Nausea tends to arrive a few hours after an injection and ease within a day or two; constipation is often more persistent than nausea for some people. Burping is genuinely common and occasionally socially inconvenient, something the patient information leaflet mentions but few people anticipate quite so literally.
Fatigue in the first week of a new dose is reported by a significant minority. Headache too. Both generally settle as the dose stabilises. The physical sensations people describe vary quite a bit, some find the first few weeks manageable from day one; others need to adjust the timing and composition of meals to stay comfortable.
There are rarer but more serious signs that require prompt medical attention. Severe stomach pain that radiates to the back (with or without vomiting) can signal pancreatitis, which the MHRA highlighted as an infrequent but serious risk in its Drug Safety Update (January 2026). If something feels wrong, contact a clinician the same day. You can also report unexpected reactions via the MHRA Yellow Card scheme.
Mood changes are less discussed but worth naming. Some people notice a dip in energy or mood during the early adjustment phase; others report the opposite as weight begins to shift. Persistent low mood or thoughts of self-harm should always prompt a same-day conversation with your GP or prescriber.
After the first couple of months, the routine tends to bed in. Injection day becomes just another diary item, the pen lives in the fridge door, you do it on a Sunday evening, done in a few seconds. If you are wondering what Wegovy is actually like to live with day to day, that is a reasonable question to explore before you start. If you are curious about what the device looks like before you start, that is a reasonable question; the pre-filled pen is straightforward to use.
Appetite at this stage feels different to dieting by willpower. Rather than resisting food, many people simply find the drive is reduced. Protein intake and hydration matter more than ever, the NHS recommends building in both alongside treatment. Strength-based activity helps preserve muscle as weight reduces. These are not optional extras; they shape how well you feel on treatment.
For context on what treatment costs privately, the Wegovy price comparison page sets out the UK market honestly, including what a single transparent price should cover. It is worth reading before you commit anywhere.
If you are ready to explore whether Wegovy is clinically suitable for you, check your eligibility through a free consultation with our prescribing team, reviewed the same day, by a real clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.